Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro
/in International Publications, Newcastle Disease Virus /von 2021-07-25 / Res Vet Sci 2021 Jul;139:159-165Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2021-07-19 / Sci Rep 2021 Jul;11(1):14661Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
/in International Publications, IOZK Veröffentlichungen /von 2021-07-04 / Cancer Immunol Immunother 2021 Jul;Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-3427
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de